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Abstract
Aim: The aim of this study was to determine whether primary nocturnal enuresis (PNE) leads to alterations in
glycosaminoglycan (GAG) excretion.
Methods: Twenty subjects (mean age 8.7 years, M/F 15/5) with PNE were included in the study. Twenty-two
healthy subjects were selected as a control group (mean age 8.7 years, M/F 14/8). Urinary GAG excretion was
measured using a modified dimethylmethylene blue (DMD) assay of 24-hour urine.
Results: The mean urinary GAG content was 33.9 mg/g and 23.8 mg/g creatinine in patients with PNE and
controls, respectively; patients with PNE thus had a higher mean GAG excretion than did age-matched controls (p
< 0.05). The association between GAG level and enuresis frequency bordered on significance (p = 0.068).
Conclusions: GAG excretion in patients with PNE was significantly higher than in normal children, suggesting that
measurement of urinary GAG may be useful in evaluating physiopathological conditions of the bladder wall.
Further studies are needed to confirm this finding.
Background
Nocturnal enuresis (NE) is defined as repeated, sponta-
neous voiding of urine during sleep in a child aged 5
years or older [1]. Available evidence indicates that NE
is best regarded as a group of conditions with different
etiologies rather than a single entity, because only a
multifactorial etiology can explain the wide range in
outcomes and the fact that different patients respond to
different therapies [2]. NE may be classified as primary
or secondary [3]. Primary nocturnal enuresis is bedwet-
ting in a child aged 5 years or over who has never been
dry for extended periods, whereas secondary nocturnal
enuresis is the onset of wetting after a continuous dry
period of more than 6-12 months [4]. Primary nocturnal
enuresis (PNE) is one of the most frequent complaints
in pediatric andurologic practice. PNE is caused by a
disparity between bladder capacity and nocturnal urine
production, and failure of the child to awaken in
response to a full bladder [5]. Despite numerous studies
on PNE, the etiology remains elusive.
Recent studies have focused on the importance of gly-
cosaminoglycans (GAGs; linear polysaccharide chains
composed of dimers of a couplet consisting of hexuronic
acid-amino sugar) that line the transitional epithelium of
the human bladder. GAGs play a structural role in the
extracellular matrix, regulate ion permeability, and have
anti-inflammatory functions on the bladder surface and
wall [6-8]. The aim of the present study was to investi-
gate variation in GAG excretion in patients with PNE.
Patients and Methods
The study included 20 children with PNE (15 boys and
5 girls, mean age 8.7 years, range 6-14 years) and 22
healthy gender- and age-matched controls.
Exclusion criteria were conditions associated with
large urine volume, abnormal neurological control, day-
time wetting, and previous use of prescription medica-
tions for enuresis. Urinary symptoms were evaluated by
taking of a history from each affected child and the par-
ents, and by use of a questionnaire and bladder diary.
All children underwent urinalysis. No child had any evi-
dence of urinary tract infection (UTI). Exclusion of UTI
was based both on urinalysis and absence of symptoms
including dysuria, urination frequency or urgency, fever,
or costolumbar or suprapubic pain. Pyuria, nitrite in the
urine, leukocyte esterase activity (LEA) in the urine, or* Correspondence: yaseminbudak2000@yahoo.com
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positive urine culture (>105 CFU/mL), were all consid-
ered evidence of UTI [9].
A dipstick test confirmed no abnormalities in pH or
urine specific gravity, and the absence of protein, glu-
cose, ketones, urobilinogen, bilirubin, or blood. All chil-
dren had normal renal function, as determined by blood
urea and serum creatinine measurements.
Urinary glycosaminoglycan excretion was spectropho-
tometrically determined in urine samples (at 520 nm)
after addition of dimethylmethylene blue (Sigma-
Aldrich, St. Louis, MO) using bovine kidney heparan
sulfate as a standard (Sigma; catalog no. H 7640) [10].
Under our experimental conditions the intra- and inter-
assay coefficients of variation were 1.5% and 2.4% for 10
mg/L glycosaminoglycan, respectively. The GAG results
were expressed as a GAG/creatinine (mg/g, respectively)
ratio.
All values are presented as means ± SDs. Statistical
analysis employed SPSS, version 10.0 (SPSS, Inc, Chi-
cago, IL). Statistically significant differences between
parameters were established using Student’s unpaired t
test. Pearson correlations were used to determine the
relationship between bedwetting frequency and urinary
GAG level. A p value <0.05 was considered to indicate a
significant difference.
Results
Of the 20 children currently bedwetting, 10 children had
nocturnal enuresis every night, 4 at least three times a
week, and 6 once or twice a week (Table 1). The mean
urinary GAG content was 33.9 ± 9.3 mg/g, and 23.8 ±
6.2 mg/g creatinine, in patients with PNE and controls,
respectively; patients with NE thus showed a higher
mean GAG excretion than did age-matched controls (p
< 0.05) (Figure 1).
Overall, the correlation between bedwetting frequency
and urinary GAG level bordered on significance (r =
0.415, p = 0.068). We consider it likely that future work
with larger numbers of patients would show a significant
correlation between GAG level and enuresis frequency.
Table 1 Bedwetting Frequency
Frequency Boys n (%) Girls n (%)
Every night 9 (45) 1 (5)
3> nights/week 2 (10) 2 (10)
<3 nights/wk 3 (15) 3 (15)
Figure 1 Mean (SD) urinary GAG/creatinine ratio (mg/g) in controls and in patients with primary nocturnal enuresis.
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Discussion
All cells apparently have GAGs on the surface, where
the molecules constitute a matrix. Because of the nega-
tive charge of sulfate, GAGs repel each other, forming a
type of cushion effect when cells interact. GAGs are
very important in directing traffic at the surface, and
constitute a necessary holding zone for many chemicals
that must mutually associate at the cell surface. GAGs
prevent small molecules from reaching the underlying
tight junctions and cell membranes, and, hence, form a
major permeability barrier [11]. Several reports on the
functional role of GAGs in the urinary tract have
appeared. GAGs are an obligatory constituent of the
basal lamina of the urothelium, contributing to mainte-
nance of transmembrane permeability and preventing
stone formation [12,13]. The presence of GAGs on the
bladder wall surface is necessary for inhibition of bacter-
ial adherence and infection, and to avoid tumor cell
implantation [14]. GAGs excreted in the urine of
healthy subjects or of patients with urological disease (e.
g., interstitial cystitis or spina bifida) are probably
derived from damaged bladder epithelium. Recently, Sal-
vaggio and colleagues found that increased excretion of
GAGs in spina bifida patients was an important para-
meter in evaluation of the physiopathological condition
of the bladder wall [15]. The cited authors found that
the wall became rich in GAG in patients with neuro-
genic bladders, leading to wall degeneration. Thus, it
was suggested that urinary GAG excretion could be a
valuable marker indicating commencement of bladder
damage.
Interstitial cystitis is often treated with exogenous
GAGs such as heparin, chondroitin sulfate, hyaluronate,
or semi-synthetic polysulfate. The mechanism of action
is presumed to be coating of the bladder surface to
replace chondroitin sulfate and heparin sulfate lost as a
result of the disease.
In the present study, GAG excretion was higher in
patients with PNE than in healthy controls. Similarly,
Ferrara and colleagues found that urinary GAG excre-
tion was significantly elevated in patients with isolated
NE compared to controls [16]. They compared GAG
excretion in 15 patients with isolated NE, and 12 NE
patients who also suffered from diurnal incontinence,
with GAG excretion in 27 healthy age-matched controls.
The cited authors suggested that measurement of GAG
excretion in such patients might be useful for evaluation
of the physiopathological condition of the bladder wall,
and hence in the monitoring of potential damage to the
bladder mucosa.
Caione and associates investigated the effectiveness of
a dextranomer/hyaluronic acid copolymer in treatment
of urinary incontinence caused by sphincter
incompetence in a total of 16 children and adolescents.
At 6, 12, and 24 months of follow-up, patients reported
improvement in daytime and nighttime dryness, respec-
tively [17].
Increased GAG excretion might result from either
immaturity of bladder innervation, or chronic exfoliation
of the bladder surface in response to infection. We sug-
gest that quantitative and/or qualitative defects in the
GAG layer might lead to reduction in functional bladder
capacity.
Although the association between bedwetting fre-
quency and urinary GAG level only bordered on signifi-
cance, analysis of a larger patient series might permit a
stastically significant association between these variables
to be demonstrated.
Despite our small sample size, the between-group dif-
ference in urinary GAG values attained statistical signifi-
cance, and we thus suggest that measurement of urinary
GAG may be useful in evaluating physiopathological
conditions of the bladder wall. Further studies are
needed to confirm the validity of this observation.
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